Desloratadine – safe and efficient medication Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
allergic rhinitis, urticaria, desloratadine
Main Article Content
Abstract
The treatment of choice for most of allergic rhinitis and chronic urticaria patients is an oral H1 receptor blocker. There are many of them on the pharma market. Desloratadine belongs to this group. Interestingly, this compound is safe and efficient across the all age groups. This paper is focused on pharmacological and clinical data regarding desloratadine.
Article Details
How to Cite
Pawliczak , R. (2015). Desloratadine – safe and efficient medication. Medycyna Faktow (J EBM), 8(2(27), 68-73. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2314
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Papi A., Papadopoulos N.G., Stanciu L.A. et al.: Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J. Allergy Clin. Immunol. 2001; 108(2): 221-228.
2. Ciebiada M., Barylski M., Gorska Ciebiada M.: Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am. J. Rhinol. Allergy 2013; 27(2): e58-e62.
3. Agrawal D.K.: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig Drugs 2001; 10(3): 547-560.
4. Bachert C.: Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56(supl. 65): 14-20.
5. Baena-Cagnani C.E.: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(supl. 65): 21-27.
6. Barecki M.E. Casciano C.N., Johnson W.W. et al.: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug. Metab. Dispos. 2001; 29(9): 1173-1175.
7. Bonini S.: Desloratadine: a new approach in the treatment of allergy as a systematic disease-pharmacology and clinical overview. Introduction. Allergy 2001; 56(supl. 65): 5-6.
8. Geha R.S., Meltzer E.O.: Desloratadine: A new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 2001; 107(4): 751-762.
9. Gupta S., Banfield C., Kantesaria B. et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 2001; 23(3): 451-466.
10. Henz B.M.: The pharmacologic profile of desloratadine: a review. Allergy 2001; 56(supl. 65): 7-13.
11. Canonica G.W., Blaiss M.: Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011; 4(2): 47-53.
12. Bachert C., Maurer M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin. Drug Investig. 2010; 30(2): 109-122.
13. Bousquet J., Bachert C., Canonica G.W. et al.: Efficacy of desloratadine in persistent allergic rhinitis – a GA(2)LEN study. Int. Arch. Allergy Immunol. 2010; 153(4): 395-402.
14. Bousquet J., Zuberbier T., Canonica G.W. et al.: Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2012; 34(3): 274-282.
15. Lukat K., Rivas P., Roger A. et al.: A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J. Asthma Allergy 2013; 6: 31-39.
16. Affrime M., Gupta S., Banfield C. et al.: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 2002; 41(supl. 1): 13-19.
17. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
18. Gonzalez-Nunez V., Valero A., Mullol J.: Safety evaluation of desloratadine in allergic rhinitis. Expert Opin. Drug Saf. 2013; 12(3): 445-453.
19. Layton D., Wilton L., Boshier A. et al.: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription- event monitoring study in England. Drug Saf. 2006; 29(10): 897-909.
20. Vuurman E.F., Rikken G.H., Muntjewerff N.D. et al.: Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 2004; 60(5): 307-313.
21. Hong J.B., Lee H.C., Hu F.C. et al.: A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J. Am. Acad. Dermatol. 2010; 63(5): e100-e102.
22. Kazmi F., Barbara J.E., Yerino P. et al.: A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 2015; 43(4): 523-533.
23. Wang E.J., Casciano C.N., Clement R.P. et al.: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos 2001; 29(8): 1080-1083.
24. Staevska M., Popov T.A., Kralimarkova T. et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010; 125(3): 676-682.
25. Augustin M., Ehrle S.: Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009; 23(3): 292-299.
26. Siebenhaar F., Degener F., Zuberbier T. et al.: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009; 123(3): 672-679.
27. Villa E., Rogkakou A., Garelli V. et al.: Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012; 5(supl. 1): S6-S13.
2. Ciebiada M., Barylski M., Gorska Ciebiada M.: Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am. J. Rhinol. Allergy 2013; 27(2): e58-e62.
3. Agrawal D.K.: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig Drugs 2001; 10(3): 547-560.
4. Bachert C.: Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56(supl. 65): 14-20.
5. Baena-Cagnani C.E.: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(supl. 65): 21-27.
6. Barecki M.E. Casciano C.N., Johnson W.W. et al.: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug. Metab. Dispos. 2001; 29(9): 1173-1175.
7. Bonini S.: Desloratadine: a new approach in the treatment of allergy as a systematic disease-pharmacology and clinical overview. Introduction. Allergy 2001; 56(supl. 65): 5-6.
8. Geha R.S., Meltzer E.O.: Desloratadine: A new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 2001; 107(4): 751-762.
9. Gupta S., Banfield C., Kantesaria B. et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 2001; 23(3): 451-466.
10. Henz B.M.: The pharmacologic profile of desloratadine: a review. Allergy 2001; 56(supl. 65): 7-13.
11. Canonica G.W., Blaiss M.: Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011; 4(2): 47-53.
12. Bachert C., Maurer M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin. Drug Investig. 2010; 30(2): 109-122.
13. Bousquet J., Bachert C., Canonica G.W. et al.: Efficacy of desloratadine in persistent allergic rhinitis – a GA(2)LEN study. Int. Arch. Allergy Immunol. 2010; 153(4): 395-402.
14. Bousquet J., Zuberbier T., Canonica G.W. et al.: Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2012; 34(3): 274-282.
15. Lukat K., Rivas P., Roger A. et al.: A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J. Asthma Allergy 2013; 6: 31-39.
16. Affrime M., Gupta S., Banfield C. et al.: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 2002; 41(supl. 1): 13-19.
17. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
18. Gonzalez-Nunez V., Valero A., Mullol J.: Safety evaluation of desloratadine in allergic rhinitis. Expert Opin. Drug Saf. 2013; 12(3): 445-453.
19. Layton D., Wilton L., Boshier A. et al.: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription- event monitoring study in England. Drug Saf. 2006; 29(10): 897-909.
20. Vuurman E.F., Rikken G.H., Muntjewerff N.D. et al.: Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 2004; 60(5): 307-313.
21. Hong J.B., Lee H.C., Hu F.C. et al.: A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J. Am. Acad. Dermatol. 2010; 63(5): e100-e102.
22. Kazmi F., Barbara J.E., Yerino P. et al.: A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 2015; 43(4): 523-533.
23. Wang E.J., Casciano C.N., Clement R.P. et al.: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos 2001; 29(8): 1080-1083.
24. Staevska M., Popov T.A., Kralimarkova T. et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010; 125(3): 676-682.
25. Augustin M., Ehrle S.: Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009; 23(3): 292-299.
26. Siebenhaar F., Degener F., Zuberbier T. et al.: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009; 123(3): 672-679.
27. Villa E., Rogkakou A., Garelli V. et al.: Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012; 5(supl. 1): S6-S13.